Merck Sharp & Dohme Corp. has described 3-oxopiperazine carboxamide derivatives acting as sodium channel protein type 10 subunit alpha (Nav1.8) blockers reported to be useful for the treatment of cough, pruritus, acute and neuropathic pain.